Fig. 3From: m6A genotypes and prognostic signature for assessing the prognosis of patients with acute myeloid leukemiaTME differences between different m6A models. A 22-Relative abundance of immune cells (B) Differences in biological pathway activity. ns p > 0.05; * p < 0.05; ** p < 0.01; ***p < 0.001; **** p < 0.0001Back to article page